ReviewJournal for immunotherapy of cancer2021
Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future.
Review in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 290 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
290 citing papers in PubMed, 2 syntheses or guidelines pooled it, 520 citations in OpenAlex.
- Two decades of immunogenic cell death research: a bibliometric analysis of the 100 most cited publications.Frontiers in oncology · 2026Pooled it
- Bibliometric analysis of photodynamic therapy and immune response from 1989-2023.Frontiers in pharmacology · 2024Pooled it
- Photodynamic antimicrobial and antineoplastic therapy in veterinary medicine: current status, challenges, and perspectives.The veterinary quarterly · 2026Review
- Imaging-guided COX-2 inhibition synergizes with photodynamic immunogenic cell death to potentiate checkpoint blockade in colon cancer.International journal of pharmaceutics: X · 2026Article
- Immunogenic Cell Death in Melanoma Induced by Radiotherapy, Photodynamic Therapy, or Non-Thermal Plasma: The Role of Reactive Oxygen and Nitrogen Species.Biomedicines · 2026Review
- Exploring chemical space for iridium(iii) complexes: a direct-to-biology (D2B) approach to identifying anticancer and antibacterial agents.Chemical science · 2026Article
- The Influence of the Central Metal (Zn) in the Porphyrin Skeleton on the Mechanism Induced by Photodynamic Therapy.Cancers · 2026Review
- Indolicidin-Decorated Photosensitizer for Enhanced Antibacterials and Accelerated Diabetic Wound Healing.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Utilizing Rationally Designed Photosensitizers to Drive Divergent Immunogenic Cell Death in Photoimmunotherapy.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Switching tumor-derived extracellular vesicles off and on via targeted proteolysis to shift toward immunogenic phenotypes.Signal transduction and targeted therapy · 2026Article
- A Deep-Red-Absorbing Osmium(II) Complex as a Photosensitizer for Photodynamic Therapy Inducing Immunogenic Cell Death.Angewandte Chemie (International ed. in English) · 2026Article
- Golden immunity: gold complexes as emerging triggers of immunogenic cell death.Chemical science · 2026Review
- Endobiliary Photodynamic Therapy in Cholangiocarcinoma: Clinical Outcomes, Patient Selection, and Procedural Context.Current oncology (Toronto, Ont.) · 2026Review
- Tumor microenvironment responsive nano-immunoregulator for precision cancer photodynamic immunotherapy.Materials today. Bio · 2026Article
- A novel photosensitizer-based photodynamic therapy reprograms the Kynurenine-AhR axis to boost antitumor immunity in breast cancer.Redox biology · 2026Article
- Laparoscopic Delivery of a MnOAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Thrombospondin-1 triggers calreticulin expression in human mucoepidermoid carcinoma MC-3 cells via the PERK/CHOP pathway.Oncology letters · 2026Article
- Co-delivery of endoplasmic reticulum-targeted photosensitizer and Ido-1 inhibitor potentiates immunotherapeutic efficacy in triple-negative breast cancer.Materials today. Bio · 2026Article
- NK cell vesicles-based nanoplatform loaded with sorafenib synergizing ferroptosis and antitumor immunity against hepatocellular carcinoma.Journal of nanobiotechnology · 2026Article
- Photo- and Immunotherapy Interface: Can Dendritic Cell Vaccines Overcome the Limitations of PDT?Pharmaceutics · 2026Review
230 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The past decade has witnessed major breakthroughs in cancer immunotherapy. This development has been largely motivated by cancer cell evasion of immunological control and consequent tumor resistance to conventional therapies. Immunogenic cell death (ICD) is considered one of the most promising ways to achieve total tumor cell elimination. It activates the T-cell adaptive immune response and results in the formation of long-term immunological memory. ICD can be triggered by many anticancer treatment modalities, including photodynamic therapy (PDT). In this review, we first discuss the role of PDT based on several classes of photosensitizers, including porphyrins and non-porphyrins, and critically evaluate their potential role in ICD induction. We emphasize the emerging trend of ICD induction by PDT in combination with nanotechnology, which represents third-generation photosensitizers and involves targeted induction of ICD by PDT. However, PDT also has some limitations, including the reduced efficiency of ICD induction in the hypoxic tumor microenvironment. Therefore, we critically evaluate strategies for overcoming this limitation, which is essential for increasing PDT efficiency. In the final part, we suggest several areas for future research for personalized cancer immunotherapy, including strategies based on oxygen-boosted PDT and nanoparticles. In conclusion, the insights from the last several years increasingly support the idea that PDT is a powerful strategy for inducing ICD in experimental cancer therapy. However, most studies have focused on mouse models, but it is necessary to validate this strategy in clinical settings, which will be a challenging research area in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.